Recruiting
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - CC-220-MM-002
Updated:
4 October, 2024
|
ClinicalTrials.gov
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Inclusion Criteria - Documented diagnosis of multiple myeloma (MM) and measurable disease. - Received 1 to 2 prior lines of anti-myeloma therapy. - Must have documented disease progression during or after their last anti-myeloma regimen. - Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. Exclusion Criteria - Any condition that confounds the ability to interpret data from the study. - Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis. - Known central nervous system involvement with MM. - Prior therapy with iberdomide. - Other protocol-defined Inclusion/Exclusion criteria apply.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information